PDCD1 and melanoma: Retrospective reviews were also conducted in studies examining anti-PD-1 therapy in patients with advanced melanoma and either preexisting autoimmune disease and/or a history of irAEs during prior treatment with ipilimumab were treated with anti–PD-1 therapy.